Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2018) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology. ISSN 0923-7534

Abstract

Metadata

Authors/Creators:
  • Urbonas, V.
  • Schadendorf, D.
  • Zimmer, L.
  • Danson, S. https://orcid.org/0000-0002-3593-2890
  • Marshall, E.
  • Corrie, P.
  • Wheater, M.
  • Plummer, E.
  • Mauch, C.
  • Scudder, C.
  • Goff, M.
  • Love, S.B.
  • Mohammed, S.B.
  • Middleton, M.R.
Copyright, Publisher and Additional Information: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Phase II; melanoma; BRAF wild-type; pazopanib; trametinib
Dates:
  • Published (online): 14 November 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 01 Feb 2019 12:55
Last Modified: 01 Feb 2019 12:55
Published Version: https://doi.org/10.1093/annonc/mdy500
Status: Published online
Publisher: Oxford University Press
Refereed: Yes
Identification Number: https://doi.org/10.1093/annonc/mdy500
Related URLs:

Download

Share / Export

Statistics